SCHEMBL4496199

SCHEMBL4496199

COc1cc2nccc(Oc3cc(C)c(NC(=O)N[C@H](C)c4ccc(F)cc4)cc3C)c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.58
PDGFRA P16234 13/20 0.58
MET P08581 6/20 0.55
AXL P30530 5/20 0.55
KIT P10721 3/20 0.55
SRC P12931 3/20 0.55
AURKA O14965 2/20 0.55
RIPK2 O43353 2/20 0.55
ABL1 P00519 2/20 0.55
EGFR P00533 2/20 0.55
LCK P06239 2/20 0.55
LYN P07948 2/20 0.55
RET P07949 2/20 0.55
HCK P08631 2/20 0.55
FLT1 P17948 2/20 0.55
FLT4 P35916 2/20 0.55
FLT3 P36888 2/20 0.55
ABL2 P42684 2/20 0.55
FRK P42685 2/20 0.55
MST1R Q04912 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483630 1.00 KDR (0.58) KDRPDGFRAMETAXLKIT
SCHEMBL4493650 1.00 KDR (0.58) KDRPDGFRAMETAXLKIT
SCHEMBL4484501 0.90 KDR (0.73) KDRPDGFRAMETAXLKIT
SCHEMBL4480033 0.90 KDR (0.73) KDRPDGFRAMETAXLKIT
SCHEMBL4477140 0.90 KDR (0.73) KDRPDGFRAMETAXLKIT
SCHEMBL4485947 0.89 MET (0.59) KDRPDGFRAMETAXLKIT
SCHEMBL4480916 0.89 MET (0.59) KDRPDGFRAMETAXLKIT
SCHEMBL4473707 0.89 MET (0.59) KDRPDGFRAMETAXLKIT
SCHEMBL4481751 0.86 KDR (0.52) KDRPDGFRAMETAXLKIT
SCHEMBL5207860 0.86 PDGFRA (0.73) KDRPDGFRAMETAXLKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-20060235033-A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor KIRIN BEER KABUSHIKI KAISHA (JP) 2006-10-19 US disclosed
EP-1535910-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR KIRIN BEER KABUSHIKI KAISHA (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235033-A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor CSF3R, CSF1R, MSR1 KDR 122/4885PDGFRA 137/4885MET 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.